Cost and cost-effectiveness studies in heart failure research

American Heart Journal

Volumn 143, Issue 4, 2002, Pages 565-576

  Weintraub, William S ^a   Cole, Jason ^a   Tooley, Joseph F ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Pharmacia

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE; ISOSORBIDE DINITRATE; RAMIPRIL; VASODILATOR AGENT;

ARTICLE; CAUSE OF DEATH; CLINICAL RESEARCH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISABILITY; DRUG COST; EVALUATION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEART FAILURE; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; INCIDENCE; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

EID: 0036238135     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.120965     Document Type: Article

References (54)

1. Cost-effectiveness analysis in clinical practice: The case of heart failure
2. Rational resource allocation in the health care system, part 1: Why rationing may become inevitable
3. Economic winners and losers after introduction of an effective new therapy depend on the type of payment system
4. Microeconomic methods in cardiovascular care
5. Productivity-cost controversies in cost-effectiveness analysis: Review and research agenda
6. Principles involved in costing
7. Analysis of costs associated with CABG and PTCA
8. The distinction between costs and charges
9. Resource use and cost of initial coronary revascularization: Coronary angioplasty versus coronary bypass surgery
10. Determinants of hospital costs in acute myocardial infarction
11. Activity based costing
12. Medicare's prospective payment system: A critical appraisal
13. Applying the resource-based relative-value scale to the emory angioplasty vs surgery trial
14. Using physician work RVUs to profile surgical packages: Methods and results for kidney transplant surgery
15. Estimating physicians' work for a resource-based relative value scale
16. Improving cost and outcome of coronary surgery
17. The meaning of utility measurement
18. Health utilities index
19. Quality of life following percutaneous transluminal angioplasty for claudication
20. The use of QALYs in health care decision making
21. Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure
22. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED trial
23. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors
24. The effect of digoxin on mortality and morbidity in patients with heart failure
25. Medical economics in cardiovascular medicine
26. Overview of randomized trials of angiotensin-converting-enzyme inhibitors on mortality and morbidity in patients with heart failure
27. Angiotensin-converting enzyme inhibitors
28. Cost-effectiveness of captopril therapy after myocardial infarction
29. An economic analysis of the survival and ventricular enlargement (SAVE) study: Application to the United Kingdom
30. Costeffectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction
31. Costs and effects of enalapril therapy in patients with symptomatic heart failure: An economic analysis of the studies of left ventricular dysfunction (SOLVD) treatment trial
32. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
33. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. ACE inhibitors in the management of congestive heart failure: Comparative economic data
34. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure
35. Socioeconomic aspects of ACE inhibition in the secondary prevention in cardiovascular disease
36. Effects of ACE inhibitors on heart failure in the Netherlands: A pharmacoeconomic model
37. The cost effectiveness of enalapril in the treatment of chronic heart failure
38. A cost-effectiveness analysis of enabpril maleate in the management of congestive heart failure in Australia
39. Cost effectiveness in the treatment of heart failure with ramipril: A Swedish substudy of the AIRE study
40. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
41. Cost effectiveness of carvedilol for heart failure
42. Economic evaluation of the cardiac insufficiency bisoprolol study for the Federal Republic of Germany
43. A cost minimization analysis of cardiac failure treatment in the UK using CIBIS trial data
44. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure
45. A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization
46. Intensive home-care surveillance prevents hospitalization and improves morbidity rates among elderly patients with severe congestive heart failure
47. Heart failure disease management: A critical review
48. Comprehensive multidisciplinary programs for the management of patients with congestive heart failure
49. Cost-effectiveness analysis of transplantation